Fleming's Technology Transfer Office (TTO) is happy to announce the granting of an international (PCT) patent application, the very first of BSRC Fleming, on Autotaxin inhibitors for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in Europe.
Fleming's Technology Transfer Office (TTO) is happy to announce the granting of an international (PCT) patent application, the very first of BSRC Fleming, on Autotaxin inhibitors for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in Europe (to be soon followed by the US, Japan, Korea, China, and Brazil). This builds on an extensive related Fleming IP portfolio, including seven granted National (OBI) patents and one additional PCT application that has also entered the National phases. The TTO is actively pursuing the exploitation and commercialisation of the related IP through public and private funding and targeted actions.